Online version, click here | To send to a friend, click here
SOLACI - NEWS
JUNE 19th, 2019   EDITION 2019 235
SCIENTIFIC NEWS

Low-Risk TAVR Trending in All Papers

TAVI bajo riesgo Transcatheter aortic valve replacement (TAVR) in low-risk patients with symptomatic severe aortic stenosis appears to be safe at one year. In a follow-up using computerized tomography (TC), hypoattenuated leaflet thickening was observed in a minority of patients, but it did not have a long-term hemodynamic impact. It should be noted that the management strategy for this finding/problem is still unclear, as is the optimal antithrombotic/antiplatelet therapy for TAVR (both general and for specific populations).

Read more HERE

Pulmonary Hypertension: No Reason for TAVR Contraindication

Denervacion pulmonarIn most severe aortic stenosis patients with pulmonary hypertension, transcatheter aortic valve replacement (TAVR) reduced pulmonary systolic pressure. There patients presented lower risk and lower all-cause mortality at short, median and long term. This data show that pulmonary hypertension should not be a TAVR contraindication.

Read more HERE

Valve-in-Valve with Self-Expanding Prosthesis: What Happens with Gradients at One Year?

Datos Excel en diabéticosDegenerated surgical bioprostheses can be safely treated with CoreValve or CoreValve Evolut using the valve-in-valve procedure. Excellent 1-year clinical and hemodynamic outcomes were achieved in a non-selected regular population, i.e., “real-world” patients.

Read more HERE

Aspirin in Primary Prevention: Another “Trendy” Topic in Publications

Pacientes EnfermedadAspirin is the standard treatment when it comes to optimal medical treatment in the context of secondary prevention of coronary artery disease, in patients with diagnosed, established atherosclerosis. Even though bleeding risk is rather small in the short period an acute event takes place, it increases substantially over time.

Read more HERE

The FDA Affirms Mortality Signs with Paclitaxel Based Devices

Pacientes EnfermedadAfter a 2-day debate, the Circulatory System Devices FDA panel has confirmed the tendency to higher mortality with paclitaxel-based devices and is expected to debate next steps and possible regulatory actions.

Read more HERE

SOLACI-SBHCI 2019 CONGRESS
SOLACI - NEWS
SOLACI - NEWS
SOLACI - NEWS
SOLACI - NEWS
SOLACI - NEWS
SOLACI - NEWS
INSTITUTIONAL NEWS
SOLACI - NEWS

SOLACI in Support of the Stent — Save a Life! Initiative

Agenda SOLACIThe Latin American Society of Interventional Cardiology has signed a cooperation agreement with the Stent — Save a Life! Initiative, a project created by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and PCR in 2009.

Read more HERE

Bolivia Sessions 2019: Clinical Case Contest for Young Interventional Cardiologists

Agenda SOLACIIt is with great pleasure that we hereby invite all young Latin American cardiologists to submit relevant clinical cases related to interventional cardiology for the upcoming SOLACI Sessions, Cochabamba 2019, to be held on August 23rd and 24th, 2019.

Read more HERE

SOLACI Agenda | The events in interventional cardiology that you can’t miss in 2019

At SOLACI we are committed to the promotion and dissemination of relevant scientific activities in the field of interventional cardiology. Therefore, below, we share a list of 2019 events that may be interesting from an educational and / or professional point of view.

Read more HERE

 
Follow SOLACI news on our social networks!
IMG  IMG   IMG  IMG
 
SOLACI Latin American Society of Interventional Cardiology
A. Alsina 2653 · FL 2°H · Buenos Aires · Argentina · Tel.Fax: (5411) 4954.7173 · www.solaci.org
The following email is being waged under Law 26.032. Such rule specifies that the search, reception and information dissemination/broadcast and ideas of all kinds, through the Internet service, is considered as coming under the constitutional guarantee that protects freedom of expression. SOLACI and / or affiliates do not intend to generate spam. According to the provisions of art. 27 of Decree 1558/01, the data owner may, at any time, request the removal or blocking of his/her name and / or data from the databases referred to the article. The regulations referred to correspond to the current legislation of the Argentine Republic. You may unsubscribe if you no longer wish to receive our emails.